Literature DB >> 12735293

Biochemical characterization of proline racemases from the human protozoan parasite Trypanosoma cruzi and definition of putative protein signatures.

Natalie Chamond1, Christophe Grégoire, Nicolas Coatnoan, Catherine Rougeot, Lucio Holanda Freitas-Junior, José Franco da Silveira, Wim M Degrave, Paola Minoprio.   

Abstract

Proline racemase catalyzes the interconversion of L- and D-proline enantiomers and has to date been described in only two species. Originally found in the bacterium Clostridium sticklandii, it contains cysteine residues in the active site and does not require co-factors or other known coenzymes. We recently described the first eukaryotic amino acid (proline) racemase, after isolation and cloning of a gene from the pathogenic human parasite Trypanosoma cruzi. Although this enzyme is intracellularly located in replicative non-infective forms of T. cruzi, membrane-bound and secreted forms of the enzyme are present upon differentiation of the parasite into non-dividing infective forms. The secreted form of proline racemase is a potent host B-cell mitogen supporting parasite evasion of specific immune responses. Here we describe that the TcPRAC genes in T. cruzi encode functional intracellular or secreted versions of the enzyme exhibiting distinct kinetic properties that may be relevant for their relative catalytic efficiency. Although the Km of the enzyme isoforms were of a similar order of magnitude (29-75 mM), Vmax varied between 2 x 10(-4 )and 5.3 x 10(-5) mol of L-proline/s/0.125 microM of homodimeric recombinant protein. Studies with the enzyme-specific inhibitor and abrogation of enzymatic activity by site-directed mutagenesis of the active site Cys330 residue reinforced the potential of proline racemase as a critical target for drug development against Chagas' disease. Finally, we propose a protein signature for proline racemases and suggest that the enzyme is present in several other pathogenic and non-pathogenic bacterial genomes of medical and agricultural interest, yet absent in mammalian host, suggesting that inhibition of proline racemases may have therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12735293     DOI: 10.1074/jbc.m210830200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Crystal structure, catalytic mechanism, and mitogenic properties of Trypanosoma cruzi proline racemase.

Authors:  Alejandro Buschiazzo; Maira Goytia; Francis Schaeffer; Wim Degrave; William Shepard; Christophe Grégoire; Nathalie Chamond; Alain Cosson; Armand Berneman; Nicolas Coatnoan; Pedro M Alzari; Paola Minoprio
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-30       Impact factor: 11.205

2.  A B lymphocyte mitogen is a Brucella abortus virulence factor required for persistent infection.

Authors:  Juan Manuel Spera; Juan Esteban Ugalde; Juan Mucci; Diego J Comerci; Rodolfo Augusto Ugalde
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-19       Impact factor: 11.205

3.  Brucella alters the immune response in a prpA-dependent manner.

Authors:  Juan M Spera; Diego J Comerci; Juan E Ugalde
Journal:  Microb Pathog       Date:  2014-02-04       Impact factor: 3.738

4.  Role of Δ1-pyrroline-5-carboxylate dehydrogenase supports mitochondrial metabolism and host-cell invasion of Trypanosoma cruzi.

Authors:  Brian S Mantilla; Lisvane S Paes; Elizabeth M F Pral; Daiana E Martil; Otavio H Thiemann; Patricio Fernández-Silva; Erick L Bastos; Ariel M Silber
Journal:  J Biol Chem       Date:  2015-01-26       Impact factor: 5.157

5.  Identification of a human trans-3-hydroxy-L-proline dehydratase, the first characterized member of a novel family of proline racemase-like enzymes.

Authors:  Wouter F Visser; Nanda M Verhoeven-Duif; Tom J de Koning
Journal:  J Biol Chem       Date:  2012-04-23       Impact factor: 5.157

6.  A Brucella virulence factor targets macrophages to trigger B-cell proliferation.

Authors:  Juan M Spera; Claudia K Herrmann; Mara S Roset; Diego J Comerci; Juan E Ugalde
Journal:  J Biol Chem       Date:  2013-05-29       Impact factor: 5.157

7.  Identification, purification, and characterization of a novel amino acid racemase, isoleucine 2-epimerase, from Lactobacillus species.

Authors:  Yuta Mutaguchi; Taketo Ohmori; Taisuke Wakamatsu; Katsumi Doi; Toshihisa Ohshima
Journal:  J Bacteriol       Date:  2013-09-13       Impact factor: 3.490

8.  Genetic immunization converts the trypanosoma cruzi B-Cell mitogen proline racemase to an effective immunogen.

Authors:  Marianne A Bryan; Karen A Norris
Journal:  Infect Immun       Date:  2009-11-16       Impact factor: 3.441

9.  Combined approaches for drug design points the way to novel proline racemase inhibitor candidates to fight Chagas' disease.

Authors:  Armand Berneman; Lory Montout; Sophie Goyard; Nathalie Chamond; Alain Cosson; Simon d'Archivio; Nicolas Gouault; Philippe Uriac; Arnaud Blondel; Paola Minoprio
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

10.  Molecular and structural discrimination of proline racemase and hydroxyproline-2-epimerase from nosocomial and bacterial pathogens.

Authors:  Maira Goytia; Nathalie Chamond; Alain Cosson; Nicolas Coatnoan; Daniel Hermant; Armand Berneman; Paola Minoprio
Journal:  PLoS One       Date:  2007-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.